Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Closes Acquisition of PersonalizeDx

NEW YORK (GenomeWeb) – Rosetta Genomics today announced that it has completed its previously announced acquisition of CynoGen, a molecular diagnostics firm doing business as PersonalizeDx.

Rosetta bought the firm from Prelude Corp., which recently acquired CynoGen from Abbott, in exchange for $2 million, 500,000 of Rosetta's ordinary shares, and certain undisclosed assets and services.

Through the deal, Rosetta has picked up PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab in Lake Forest, Calif. Also included in the deal is Prelude's assay for ductal carcinoma in situ, a prognostic test designed to differentiate stage 0 breast cancer patients at high and low risk for disease recurrence, as well those likely to respond to therapy versus those who are not.

Rosetta said that PersonalizeDx recorded 2014 revenues of $6.9 million. Following the acquisition, Rosetta anticipates its 2015 revenues will be in the range of $10 million to $12 million, and its 2016 revenues will exceed $18 million.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.